Abivax
Abivax SA is a French clinical-stage biotechnology company focused on developing therapies that modulate the immune system to treat chronic inflammatory diseases. The company operates through a single biopharmaceutical research and development segment, centered on its lead drug candidate, obefazimod. Its potential future revenue drivers stem from clinical trial progression, regulatory licensing approvals, commercialization agreements, and prospective pharmaceutical sales for autoimmune indications. Abivax concentrates its research on ulcerative colitis, Crohn's disease, and other severe inflammatory conditions, conducting advanced global clinical trials across Europe and North America. The enterprise holds a recognized position within the biopharmaceutical sector as a developer of novel small-molecule RNA modulators with anti-inflammatory properties. The company focuses strategic resources on executing late-stage Phase 3 clinical trials, securing global regulatory pathways, and expanding its intellectual property portfolio. Abivax SA is headquartered in Paris, France, and its common shares are listed on Euronext Paris alongside American Depositary Shares on the Nasdaq Global Market.
24 of the funds FundTelligence covers report a position in Abivax.
- Legal name
- Abivax SA
- Sector
- Health Care
- Country
- France
- Funds holding it
- 24
Funds holding Abivax
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 1.9 % (partially disclosed portfolio, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.91 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.31 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 0.28 % (full portfolio disclosed, October 2026)
- Storebrand Europe Index — Storebrand · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeEuropa Indeks — KLP · 0.05 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI Europe Screened UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 24 funds holding it.